MedTrace Logo

Effect of H. Pylori Eradication on Alleviating Symptoms in Functional Dyspepsia Patients

NCT05786807 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2023-03-28

No results posted yet for this study

Summary

In patients with Helicobacter pylori-positive functional dyspepsia, long-term follow-up for 6 months after standard triple therapy first-line eradication treatment, the rate of symptom disappearance and degree of improvement of functional dyspepsia were confirmed through changes in symptom scores and changes in drug usage, and eradication treatment The purpose of this study is to confirm the rate of symptom disappearance according to the results.

Conditions

  • Helicobacter Pylori-positive With Functional Dyspepsia

Interventions

DRUG

K-CAB

Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily

Sponsors & Collaborators

  • Wonkwang University Hospital

    lead OTHER

Principal Investigators

  • Suck Chei Choi · Wonkwang University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-07
Primary Completion
2023-11-30
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05786807 on ClinicalTrials.gov